Solta Medical (NASDAQ:SLTM) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued to investors on Monday, AnalystRatingsNetwork reports. The firm currently has a $3.00 price target on the stock. Zacks‘ price objective would indicate a potential upside of 2.39% from the stock’s previous close. Solta Medical (NASDAQ:SLTM) […]
Solta Medical Upgraded by Zacks to Neutral (SLTM) is a post from: Zolmax
The post Solta Medical Upgraded by Zacks to Neutral (SLTM) appeared first on Zolmax.